Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• Päätekijät: Qiao Liu (Tekijä), Zhen Zhou (Tekijä), Xia Luo (Tekijä), Lidan Yi (Tekijä), Liubao Peng (Tekijä), Xiaomin Wan (Tekijä), Chongqing Tan (Tekijä), Xiaohui Zeng (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...